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ABSTRACT 
 
 
 
 The purpose of this IQP was to investigate stem cell technology, examining a variety of 
stem cell types, as well as the ethics and legalities surrounding their research.  This report 
investigated various stem cell types and sources, current medical applications, ethical issues 
associated with each type, and legal stances the world has on this research.  We conclude that 
embryonic stem (ES) cells have the greatest medical potential, and the greatest ethical and legal 
concerns.  Adult stem cells are more difficult to grow, and have less differentiation potential.  
New alternative technologies have been developed to avoid the destruction of embryos to obtain 
ES cells, and we support these efforts.  We conclude that of the five major world religions, 
Christianity (especially Catholics) and Buddhism oppose ES cell research, while the 3 others are 
somewhat supportive of it.  All five support adult stem cell research.  Legal restrictions placed on 
stem cell research by countries such as the U.S. and Germany have hindered research into ES 
cells relative to other more progressive countries.  
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PROJECT OBJECTIVES 
 
 
 The purpose of this project was to explore the breadth of the topic of stem cells and go 
beyond a discussion of the technology to include the effect of the technology on society.  The 
purpose of Chapter-1 was to describe properties of stem cells and note that there are more types 
of stem cells than just embryonic stem cells.  The purpose of Chapter-2 was to go in depth on 
which experiments stem cells have been successfully used for, to illuminate their potential as a 
prelude to discussing their ethics.  The purpose of Chapter-3 was to explore the ethics 
surrounding this controversial topic to assess their effect on society.  The purpose of Chapter-4 
was to determine the extent of stem cell use as governed by current Federal, state, and 
international laws.   
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CHAPTER-1:  STEM CELL TYPES AND SOURCES 
 
  
 Stem cells have become a hot topic among many in the field of biology due to the 
wonderful properties they possess, compared to most other types of cells that constitute the 
human body.  A stem cell is a type of cell that is characterized as being undifferentiated, 
meaning that depending on the conditions it encounters, it can be programmed to develop into 
another specialized tissue or organ of the body.  Ever since decades ago, stem cells have been 
used in extensive studies.  Through various experiments, stem cells have been used as simple 
tools for understanding critical molecular mechanisms behind human development.  In the field 
of medicine they have been used to treat various diseases.  Interestingly enough, stem cells do 
not just come from five-day old blastocyst-stage embryos, which are associated with serious 
ethical concerns, as we will see later.  They are in turn obtained from two general sources:  adults 
as well as embryos.  In turn, based on how well the cells differentiate, they are characterized by 
levels of potency:  totipotent, pleuripotent, multipotent, and unipotent.   
 
Overview of Stem Cell Types 
 It is necessary at this point to note that not all stem cells are alike, to contrast the common 
notion that all stem cells are alike or similar.  Thus, when it comes to someone saying that he or 
she is against stem cell research, it is necessary to greatly distinguish what kind of stem cell 
research one is against.  As mentioned before, stem cells are classified into two major categories:  
embryonic and adult, and further into levels of potency:  totipotent, pleuripotent, multipotent, 
and unipotent.  Newly fertilized eggs through about the 8-cell stage of development are 
totipotent, meaning they are capable of forming any cell in the body, or the placenta.  Embryonic 
stem cells, or ES cells, are pleuripotent, able to form almost any cell in the body.  Hematopoietic 
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stem cells (HSCs) are multipotent, able to form several types of related cells (i.e. white blood 
cells, red blood cells, platelets, etc).  Mesenchymal stem cells (MSCs) are also multipotent.  
Cells such as skin stem cells are usually regarded as unipotent, able to generate only other skin 
cells. 
 
Embryonic Stem Cells 
 Embryonic stem cells originate from the inner cell mass of a blastocyst, or an embryo in 
its very early stage of development of only five days.  At this time, the fertilized zygote exists as 
an approximately 150-celled organism.  Here, the blastocyst’s basic structure consists of two 
layers of distinctive cells:  the outer layer of trophoblastic cells, and the inner cell layer, where 
the stem cells exist (see Figure-1).   
 
 
 
 
 
Figure-1:  Formation of a Human Blastocyst 
with Differential Potentials.  Egg and sperm 
are united during in vitro fertilization (upper 
left) and grow to the 4-8 cell stage (morula, 
green), and continue growing for about 5-6 
days to make a blastocyst (upper right, yellow).  
Within the blastocyst is the inner cell mass 
(blue) that contains ES cells, which can 
differentiate into a variety of tissues (lower 
portion of diagram).  
 (Stem Cells, 2008). 
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ES cells are pleuripotent, meaning they have the potential to differentiate into almost any 
cell of the human body (Frequently Asked Questions, 2006).   The process of cultivating ES cells 
requires extraction of cells from the inner cell mass, and this extraction causes the embryo to 
cease to exist.  Thus, one can argue that taking cells from the inner cell mass is immorally 
destroying a potential human’s right to live, which is quite a debate as will be discussed later in 
Chapter 3.   However, scientists have recently devised alternate methods of ES cell production, 
including parthenogenesis, somatic cell nuclear transfer, and induced pleuripotent ES cells, as 
will be discussed later in this chapter.  And adult stem cells can sometimes be used in lieu of ES 
cells, for certain medical applications as an alternative to ES cells. 
 
Adult Stem Cells 
 In comparison, adult stem cells, or ASCs, are undifferentiated cells found in several parts 
of the human body, especially in certain organs and tissues (Frequently Asked Questions, 2006).   
Recent research has shown that they also come from fetal cord blood, baby dental pulp, and 
amniotic fluid.  The main purpose of ASCs is to repair damaged tissue, and help organs replenish 
themselves.  Thus in theory, ACSs exist with a lower level of potency than ES cells, and have a 
limit as to which types of cells they can become.  However, this is not completely true, as a 
handful of certain types of adult stem cells, including MSCs and HSCs, have some evidence for 
plasticity (ability to differenti- ate into a type of tissue different than the one from which they 
were isolated) (Kirschstein, 2001).   
 ASCs prove a valuable source of stem cells to work with, because no embryo is destroyed 
to obtain them, yet they are associated with some inconvenient disadvantages.  They are rare, 
they do not exist in numerous quantities in the organs they originate from, and scientists must 
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rely on a handful of extraction, analytical, and purification methods to capture the light of these 
cells, that are considerably tedious.  They are also less potent than ES cells, however, some 
studies have shown hints that such cells may have the potential to trans-differentiate into 
multiple cell types (Kirschstein, 2001).  It has not been proven, however, that this can occur in 
vivo, but many in the scientific community do embrace the possibility, and argue such cells 
would help replace ES cells. 
  
Hematopoietic Stem Cells (HSCs) 
 These are stem cells that are isolated mainly from the bone marrow, fetal umbilical cord 
blood, or from the peripheral blood of a person, say, who has undergone hormonal therapy to 
encourage the release of such cells into the blood from the bone marrow.  Such stem cells, when 
exposed to their associated typical conditions, give rise to all the types of blood cells, including 
those associated with the immune system.  These cells include not just red blood cells, but also B 
and T lymphocytes, natural killer cells, neutrophils, basophils, eosinophils, monocytes, 
macrophages, and platelets.  This property dubs hematopoietic stem cells as multipotent stem 
cells, as they can differentiate into many cell types, and in turn they continue to be used 
especially in immunological-related treatments (see Figure-2 for the typical differentiation 
pathways of a hemato- poietic stem cell).  It has been recently known that HSCs from cord blood 
have been used to treat over forty life-threatening diseases, including blood-related cancers, 
certain genetic diseases, immune system deficiencies, and blood diseases (Viacord, 2008).   
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Figure-2:  Diagram of Hematopoiesis.  Hematopoietic stem cells (left, center) 
differentiate into lymphoid (upper) or myeloid (lower) lineages that form all the cellular 
components of blood.  (National Academy Press, 2001). 
 
 
Mesenchymal Stem Cells (MSCs) 
 Also known as bone marrow stromal stem cells, these cells, like hematopoietic cells, also 
originate typically from the bone marrow.  When grown under specified conditions in vitro in the 
laboratory, however, they differentiate into osteocytes, chondrocytes, adipocytes, and connective 
tissue cells, which in turn work together to form tissues such as bone, cartilage, fat, tendons, and 
ligaments (Kirschstein, 2001).  Mesenchymal stem cells have even been found to differentiate 
into some muscle components.  Such an ability of MSCs differentiating into a wide array of cells 
gives them the greatest variety of specialization among all other types of adult stem cells.  Thus, 
they will increasingly be relied on in the medical community.   
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Figure-3:  Differentiation of Bone Marrow Hematopoietic and Stromal Stem Cells.  The 
bottom half of this diagram shows the differentiation of mesenchymal stem cells into their 
components (Kirschstein, 2001). 
 
 
Neural Stem Cells (NSCs) 
 These cells are found mainly in the human brain (especially in the hippocampus and the 
olfactory bulb), and in the spinal cord in the central nervous system.  Typically they differentiate 
into three major cell types:  nerve cells, or neurons; and two major categories of “non-neuronal” 
cells:  astrocytes and oligodendrocytes (Frequently Asked Questions, 2006).  Astrocytes and 
oligodendrocytes serve to support and nourish precious nerve tissue.  Neural stem cells are 
currently under extensive research to treat critical disorders such as Alzheimer’s Disease or 
Parkinson’s, and experiments involving such studies have been done in mice so far, as will be 
discussed in Chapter-2. 
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Epithelial, Skin, and Cardiac Stem Cells 
 Epithelial stem cells, or ESCs, are unique adult stem cells that originate from 
continuously self-rejuvenating linings of epithelial tissue, including the gastrointestinal digestive 
tract, some parts of the skin, and the adult eye.  ESCs appear to be more unipotent than 
multipotent compared to the other adult stem cell types, as they form a number of tissues only 
dependent on where they originally came from.  For instance, those produced in the deep crypts 
of the digestive tract’s lining differentiate only into such cells including absorptive cells, goblet 
cells, Paneth cells, and enteroendocrine cells (Kirschstein, 2001).   
 In comparison, skin stem cells are absolutely unipotent.  In such a case, these stem cells 
are classified as having the highest degree of specificity and can just give rise to only one other 
cell type.  Skin stem cells are born from only two places in the skin:  the epidermis’ basal layer, 
and at the base of hair follicles.  From these areas, skin stem cells give rise to keratinocytes 
which migrate to form a protective layer at the surface of the skin, and they also form parts of the 
hair follicle and the epidermis (Kirschstein, 2001).  Although epidermal stem cells are unipotent, 
they actually have advantages that make them reliable in transplantation therapy and molecular 
research.  One of these great advantages is that since they can only differentiate into one kind of 
body cell, they are easier to study in molecular terms.  Other advantages include that skin stem 
cells are easy to extract and have a great ability to self-renew, and they can be used to form skin 
grafts in effectively treating burns and other injuries on a patient’s body, without any risk of 
immunorejection since the cells would come straight from the patient’s own body.   
 Cardiac stem cells (CSCs), compared to epidermal stem cells, are unipotent stem cells 
that rise from the heart muscle and give rise to only one type of tissue:  the cardiac tissue.  So far, 
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CSCs have been used in case studies involving humans as well as laboratory mice in healing and 
repairing damaged heart tissue.   
 
Current Alternative Strategies to Embryo Destruction  
 Recently cell and molecular biologists have been developing promising strategies for 
obtaining ES cells without destroying an embryo.  These alternatives include parthe- notes, iPS 
cells, and single cell micromanipulation.   
 
Parthenotes 
An alternative strategy that researchers have developed within the past few years that can 
give rise to pleuripotent ES-like cells is known as parthenogenesis.  Under this method, a non-
fertilized egg is stimulated through chemical treatment such as strontium chloride to divide, as if 
it was a fertilized egg, until it has reached the blastocyst stage.  At this point, ES cells can be 
obtained, but no further division occurs by the egg.  As the original egg was not fertilized and the 
resulting “embryos” have no potential to develop into human beings, their place in the field of 
stem cell research is taken much more lightly than ES cells by ethicists.  So far, primate 
parthenote ES cells were successfully derived in 2001 (Cibelli et al., 2002), and human 
parthenote ES cells in 2007 (Kim et al., 2007).  Thus, parthenotes may serve as an alternate 
source of ES cells in the years to come.  However, this technique would only work for the 
derivation of ES cells from a female patient, since only females can donate the original egg. 
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Figure-4:  Digital Photograph of a Human Parthenote.  Photo of a human  
ovum fifteen hours after chemical parthenogenetic activation (An Alternative  
to Cloning, 2005). 
 
 
 
Single-Cell Micromanipulation 
Some very recent studies document techniques that allow single cells to be extracted 
from an early stage embryo (usually the 8-cell stage) or from a blastocyst without destroying the 
embryo (Chamany, 2004).  These techniques are termed single-cell biopsy or micromanipulation, 
which involve the extraction of only a very small quantity of ES cells without affecting 
subsequent development of the embryo.  Because such an embryo could in theory still be used 
for reproductive purposes, it may have less ethical concerns than destroying a viable embryo.  In 
June 2006 a team of researchers headed by M.D. Robert Lanza of Advanced Cell Technology in 
Worcester, MA carried out a single-cell biopsy on an eight-cell human embryo, to produce four 
ES cell lines (Markwith, 2006).  The biopsied embryo was then placed in cryogenic containment, 
and later was found to still be a viable embryo.  The ACT team especially made note that this 
technique is very much similar to preimplantation genetic diagnosis, in which a single cell 
extraction does not interfere with the embryo’s developmental potential (Lanza et al., 2006).   So 
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far, these techniques are only at their early stages of development, and it may actually take 
awhile until it they are proven to work effectively. 
 
Induced ES (iES) Cells 
 A lesser controversial strategy for obtaining ES cells is the creation of induced ES (iES) 
cells.  More commonly known as induced pleuripotent (iPS) cells, these are initially non-
pleuripotent adult cells (usually skin fibroblast cells which are convenient to obtain) that are 
genetically engineered to behave like pleuripotent ES cells.  iES cells are produced by inserting 
copies of combinations of three to four genes [encoding transcription factors known to induce a 
de-differentiated state (Takahashi et al., 2007)] into fibroblast cells using retroviruses 
(Frequently Asked Questions, 2006).   
The technique was originally devised in June 2006 in Japan by the molecular biologist 
Shinya Yamanaka of Kyoto University.  He collected skin fibroblast cells from mice and 
reprogrammed the cells to an ES-like state by transferring four genes encoding four transcription 
factor proteins with the aid of retroviruses.  Retroviruses are commonly used in genetic 
engineering to incorporate bits of molecular information into genomes.  Because no embryos are 
destroyed in this process, such iES cells have far fewer ethical considerations than traditional ES 
cells.  This technique (like SCNT) might also be used to create ES cells compatible with a 
specific patient; it could be applied to a patient’s fibroblast cell.  So far, the technique has been 
achieved with mouse cells (Cyranoski, 2007), and human cells (Takahashi et al., 2007; Yu et al., 
2007; Park et al., 2008).  It is, however, unknown how safe iPS cells will be to treat human 
disease without causing cancer, for example. 
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Somatic Cell Nuclear Transfer (SCNT) 
 Recently, researchers have attempted to devise a protocol for preparing ES cells 
genetically identical to a specific patient.  Such patient-compatible stem cells would presumably 
not be rejected by the host during engraftment.  In this technique, known as somatic cell nuclear 
transfer (SCNT) procedure, an enucleated egg whose nucleus has been removed is microinjected 
with the nucleus of any typical cell from a specific patient.  As when producing iPS cells, skin 
fibroblast cells are usually used since such cells are convenient to obtain.  Once the oocyte is 
treated with the genetic material of an adult somatic cell, it is then stimulated to undergo cell 
division as if it had had been fertilized by a sperm cell, just as in parthenogenesis (Chamany, 
2004).  Once the dividing egg reaches the blastocyst stage, ES cells can be isolated genetically 
identical to the patient.  As this is so, SCNT is particularly thought of as a way to obtain ES-like 
cells to treat patients without running the risk of immunological rejection upon tissue 
transplantations.  Thus, it can be referred to at times as a therapeutic cloning.  So far, SCNT has 
been used to clone primate ES cells (Byrne et al., 2007), however, the original claim of SCNT 
success in humans (Hwang et al., 2005) was later retracted, so this technique has not yet been 
achieved in humans. 
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Figure-5:  Diagram of the SCNT Technique.  A mature oocyte (upper left) is obtained 
and its genome is removed (upper center), and is replaced (upper right) with the nucleus 
of an individual’s fibroblast skin cell (upper right).  The embryo is grown to the 8-cells 
stage (center), then grown to the blastocyst stage (lower left), from which ES cells are 
obtained (bottom) that are genetically identical to the patient (Embryonic Stem Cells, 
2007). 
 
Research in this area indicates caution is necessary, as mouse models have revealed that 
SCNT clones often have aberrant genomic imprinting patterns, or chemical modifications of 
DNA (Chamany, 2004).  The efficacy of producing viable offspring is very low, and a majority 
of embryos produced by this method experience developmental abnormalities and/or the 
offspring die shortly after birth (Chamany, 2004).   It has yet to be determined whether ES cells 
derived by SCNT will show similar abnormalities. 
 
Chapter-1 Conclusion 
 To date, with so many different types of stem cells isolated, each with their own benefits, 
it can be well inferred that stem cell research has come a very long way since their discovery in 
mice in the 1960’s.   The purpose of this chapter was to document the different types of stem 
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cells, paying special attention to which ones require the destruction of an embryo, and which 
ones do not, as a lead into the ethics discussion in Chapter-3.  We shall now move on to discuss 
in the next chapter the myriad of invaluable applications of specific stem cells in detail. 
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Chapter 2:  Stem Cell Applications 
 
Although the previous chapter described the existence of many different types of stem 
cells, not all of them have been proven to have medical applications at this time.  The purpose of 
this chapter is to outline some stem cell applications that have successfully been done with 
several types of diseases. 
 
Treatment of Diabetes with Stem Cells 
Embryonic stem (ES) cells have the most medical potential of all types of stem cells due 
to their ability to differentiate into almost any type of tissue.  ES cells have been used for a 
variety of applications, but are best documented for the treatment of diabetes.  This autoimmune 
disease causes the destruction of pancreatic islet beta cells, which in turn affects the amount of 
insulin the body produces.  One early study done in vitro utilized pluripotent undifferentiated 
human embryonic stem (hES) cells in adherent and in suspension cultures, to demonstrate their 
differentiation into beta cells with the ability to produce insulin.  The release of insulin by these 
differentiated cells in culture was documented using beta cell markers.  This study demonstrated 
the ES cell potential for treating this disease, and gives a positive outlook on future use of such 
cell lines to be used in cell replacement therapy for diabetic patients.   When obtaining such 
results, hES’s are grown as undifferentiated colonies in culture.  These cells are usually placed 
on a feeder layer of mouse fibroblasts.  In some cases, embryoid bodies (EB’s) form, comprised 
of all three embryonic layers, ectoderm, mesoderm, and endoderm.  Through the use of Reverse 
Transcriptase Polymerase Chain Reaction (RT-PCR) performed on RNA isolated from the hES 
cells, differentiated cell lines were detected that produced mRNA encoding insulin protein.   
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In addition, immunostaining was also performed to demonstrate insulin production 
(Figure-1).  After embryoid bodies “EB’s” were seen in culture, cells were isolated every 3 days 
for a total of 19 days.  After about the 14
th
 day, insulin producing cells were evident, as tested by 
immuno-histochemical staining, and these positive cells became progressively more evident at 
day 19 where approximately 60-70% of the cells stained positive for insulin (Figure-1).  These 
findings
 
validate the hES cell model as a potential system for producing insulin during cell 
replacement therapy for diabetes. 
   
 
 
 
 
 
 
 
 
 
 
 
Recently, James Shapiro and his colleagues (Edmonton, Canada) developed a means of 
transplanting large amounts of pancreatic islet cells into patients using immuno-suppressant 
therapy, allowing the cells to easily adapt and thrive in the patient’s body (Stem Cells and 
Diabetes, 2005).  All seven patients undergoing this procedure progressed to the point that about 
Figure-1:  Picture of Human ES Cells Differentiated to 
Embryoid Bodies That Produce Insulin.  The reddish brown 
color denotes positive immunostaining for insulin protein.  
Panel-A, normal human pancreas (40X) (positive control); B-
D, differentiated embryoid bodies at day-19 (40X); E, EB at 
day-19 (100X); F, EB at day-19, nonimmune negative control.   
(Assady et al., 2005) 
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a year after surgery they no longer needed insulin injections.  This technique is now being tested 
in 10 of the world’s most prestigious research centers.  However, the drawback of this procedure 
is the limited amount of islet cells available for transplant.  Currently, these cells are taken from 
cadavers, so this is where hES cells comes into play.  If scientists can culture hES cells and 
differentiate them successfully into islet cells producing sufficient amounts of insulin, the need 
for cadavers and the low quantity of such cells will be a thing of the past.   
One key question in ES diabetes research is how to optimize the production of insulin.  A 
recent finding indicates cells surrounding the beta cells help this production.   Through research 
it has been discovered that beta cells that are surrounded by other types of islet cells are more 
efficient and responsive to changes in glucose levels than those found in solidarity, such as beta 
islet cells on their own.  Scientists have discovered that differentiated isolated beta cells 
sometimes release insulin in an all or nothing sequence, which could have detrimental effects on 
a patient.  Culturing a cluster of all the islet cells together allows them to work in harmony 
producing the appropriate amount of insulin at the right time.  
  Recently, researchers are trying to develop methods for avoiding immuno-rejection of 
the beta cell transplants.  This can be done by placing the cultured cells into a nonimmunogenic 
material before transplantation allowing less chance of rejection.  Researchers are also trying to 
utilize the technique of somatic cell nuclear transfer (SCNT) for making ES cell lines specific for 
one patient.  In this technique, a nucleus is isolated from a skin fibroblast cell from a patient, and 
then is microinjected into an enucleated ES cell, so the ES cell line is genetically compatible 
with the patient.  However this procedure has only been done with mice and primates, and has 
not yet been done with humans (Stem Cells and Diabetes, 2005). 
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           Researchers in Spain have recently discovered a way to select ES cells while they are 
differentiating, making it easier to select for the insulin producing cells (Stem Cells and 
Diabetes, 2005).   The cells are grown in an antibiotic rich media where only the insulin 
producing cells survive.  These cells were then cloned and transplanted into diabetic mice 
eventually reversing the effects of the disease.  When transplanting these cells into the mice, 
great care was taken to avoid transplanting outlying cells that could give rise to tumors that could 
be life threatening.  Figure 2 shows embryoid bodies made up of all three embryonic germ 
layers.  The cells that contained the beta cell marker insulin were then extracted and utilized in a 
five step culturing system to produce clusters of islet performing cells (Stem Cells and Diabetes, 
2005) (Figure-2). 
 
 
 
 
 
 
 
Figure-2:  Diagram of the Culture 
of Mouse ES Cells Used to Treat a 
Diabetic Mouse.  Mouse ES cells 
were isolated from in IVF blastocyst 
(upper right), then cultured on a 
feeder layer and differentiated 
(center right).   The cells were 
screened for insulin producing cells 
(lower right) then transplanted into a 
diabetic mouse (lower center).  Inset 
shows the lowering of blood glucose 
in the transplant mice.  (Stem Cells 
and Diabetes, 2005). 
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Treatment of Damaged Heart Muscle Using Stem Cells 
  
          
   The damage of heart muscle cells (cardiomyocytes) results in health problems such as 
heart attacks, coronary artery disease, hypertension, and other debilitating symptoms, that can 
negatively affect the heart and its surrounding organs.  Through use of stem cells, doctors are 
trying to transplant new differentiated cardiomyocytes into the heart itself which will take the 
place of the damaged cells, and which will allow the heart to repair itself.  Cardiomyocytes 
contract allowing blood to flow throughout the body.  Researchers have discovered that under 
specific growth conditions, mouse and human ES and hematopoietic stem cells can be 
differentiated into both cardiomyocytes, as well as vascular endothelial cells, both of which help 
conduct blood throughout the body.  Transplanting cultured, working heart tissue into a patient’s 
damaged heart instead of transplanting an entire heart from another person would be much easier 
and more effective long term.  
            One example of this stem cell procedure involves hematopoietic stem cells (HSCs) taken 
from adult mouse bone marrow (NIH Stem Cell Information, 2001).  After a heart attack was 
surgically induced in a mouse by tying off a major blood vessel, HSCs were injected into the 
damaged area of the heart.  The mice that received these HSC injections showed a much greater 
rate of recovery from the induced heart attacks than those that did not.  The injected stem cells 
eventually formed new cardiomyocytes, as well as vascular endothelium and smooth muscle 
cells, all of which are needed to successfully create new heart and blood vessel tissue.  The study 
concluded that the transplanted HSCs were triggered by the injured myocardium to migrate and 
differentiate leading to a healthy working heart.  
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           Another study showed that human adult HSCs can be taken from a donor’s bone marrow 
and injected into a rat model for heart attacks where they differentiated into vascular endothelial 
cells (Figure-3) (NIH Stem Cell Information, 2001).  Similar to the mouse study, this rat study 
was also performed by inducing a heart attack by tying off the main coronary artery.  The human 
HSCs were injected into the blood vessels of the rat, and the damaged area was then repaired. 
 
 
 
 
 
 
 
 
 
 
 
 
            In these experiments, specific HSC markers were used to identify and purify HSCs from 
other cells, which increased the therapeutic potential of the graft.  Their purification was aided 
by the use of antibodies that tagged proteins on the surface of HSCs specific for this cell type.  
Once the HSCs had been tagged with the antibodies containing a fluorescent label, those 
fluorescing cells were purified by fluorescent activated cell sorting (FACS). 
Figure 3: Diagram of the Injection of Human HSCs 
into a Rat Heart.  HSCs isolated from bone marrow 
(left side) are injected into the heart ventricle (diagram 
center), and subsequently differentiate into cardiac 
muscle (right side) (New Stem Cell, 2005). 
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            In addition to using HSCs, ES cells have also been used to treat heart attacks in animal 
models (NIH Stem Cell Information, 2001).  In one study, hES cells were first differentiated in 
culture into embryoid bodies containing all the three embryonic germ layers, and the final data 
was promising.   
Some recent work has also been done with autologous transplants using a patient’s own 
HSCs.  The University of Pittsburgh Medical Center is testing the use of a patient’s own bone 
marrow derived stem cells and injecting them directly into the heart muscle.  This treatment is 
being researched as a potential cure for congestive heart failure.  This research will be the first 
time that scientists will be able to observe the results of such a procedure in a human heart.  All 
patients in this study must have a ventricle assist device (VAD) implanted, which will be utilized 
as a bridge for stem cell attachment.  The patient’s bone marrow is harvested from the hip bone 
where it is then directly injected into the site during the (VAD) surgical procedure.  Once the 
patient has been equipped with the VAD leading to the heart, 20 to 40 different injections will be 
conducted into the heart depending on the patient’s weight, each containing 30-40 million stem 
cells mixed with blood plasma.  A negative control containing only blood plasma is used to 
allow the researchers to observe what effects the stem cells actually have on the cellular 
structures surrounding the heart (Kormos, 2005). 
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Use of Stem Cells to Treat Parkinson’s Disease 
 
A group of doctors in Israel have discovered a way to differentiate ES cells into the brain 
neuronal cells that Parkinson’s patients have lost (Ben-Hur et al., 2004).  Parkinson’s patients 
lose cells in an area of the brain termed the substantia nigra that is involved in dopamine 
production.  Without the production of this key dopamine neurotransmitter, patients show 
diminished neuroskeletal coordination, and a difficulty initiating movement. The scientists 
utilized human ES cells to treat a rat model for this disease.  This was actually the first time that 
these types of stem cells had been used effectively to treat an animal with this disease.  The 
human ES cells transplanted into the rodent brains allowed them to show behavioral 
improvements.  They stopped turning continuously in circles, and when dragged across a surface 
they began to be able to side step, where before treatment these rats lacked these specific motor 
skills.  When the rats were tested at autopsy, results showed that the transplanted ES cells had 
differentiated into neuronal cells producing dopamine.  
 One problem that arose in this (Ben-Hur et al., 2004) study was that some of the 
transplanted ES cells did not fully proliferate and differentiate into dopamine-producing cells.  
This can be very dangerous to the patient, possibly causing death and or brain damage to that 
region.  Dr. Benjamin Reubinoff who is the leader of the Israeli group of doctors says that such 
results are very promising for future use in human patients, yet there are still too many questions 
about the treatment that need to be answered before this type of treatment can be conducted in 
humans.  This type of treatment in humans may also be more difficult than in rats because of 
difficulties that accompany the production of clinical grade stem cells which must be free from 
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viruses, and also to conduct longer trials to make sure that cancerous tumors do not form from 
treatment (Ryan, 2004). 
 Patients with Parkinson’s disease have also received treatment through receiving their 
own adult neural stem cells (NSCs), which were cultured into dopamine producing neurons.  
These modified NSCs were then injected into patient’s the left side of the brain which controls 
the right side of the body affected most strongly in this patient.  The patient in this study is 
known as Dr. Dennis Turner who was treated by Dr. Levesque.  Dr. Turner testified in front of 
the US senate committee on his progress and recovery from surgery which showed positive 
results.  He states that soon after the cells were injected into his brain, his Parkinson’s symptoms 
gradually began to decline until the point where normal function was recovered on the right side.  
The patient was able to do all the activities of a normal healthy human being whom never 
acquired Parkinson’s (Stem Cell Therapy, 2004).  Dr. Turner indicated during his testimony to 
the U.S. Senate Committee, “Since being diagnosed with Parkinson’s disease my condition had 
slowly, but continuously worsened.  I can’t say with certainty what my condition would have 
become if Dr. Levesque had not used my own adult stem cells to treat me.  But I have no doubt 
that because of this treatment I’ve enjoyed five years of quality life that I feared had passed me 
by” (Dr. Turner, 2004). 
      In a similar study with Parkinson’s, instead of the patients receiving adult stem cells, 
they received an injection of a protein known as glial cell line derived neurotrophic factor 
(GDNF).  This protein is known to stimulate the patient’s own adult stem cells in the areas of the 
brain affected by Parkinson’s.  The study was closely observed for about a year, and all five of 
the patients that had this procedure showed about a 60% increase in movement and coordination, 
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as well as a lessened severity of the symptoms they were exhibiting one year before (Stem Cell 
Therapy, 2004). 
 A similar study to Dr. Turner’s was performed on monkeys in Japan at Kyoto University.  
Researchers used adult monkey stem cells that generated dopamine releasing neurons.  These 
neurons were then transplanted into the brains of monkeys suffering from Parkinson’s.  The 
results showed a full recovery from the symptoms. Instead of injection at numerous sites like in 
Dr. Turner’s case, transplantation of these cells was performed directly to the areas of the brain 
that were affected.  This study shows that under certain conditions, adult stem cells can be 
differentiated into healthy neuronal cells, eventually reversing the effects of the disease (Stem 
Cell Therapy, 2004). 
 
Use of Stem Cells for Spinal Cord Injuries    
 Human embryonic stem cells (hES cells) were recently used on the campus of UC Irvine 
to improve the mobility of rats suffering spinal cord injuries.  Researchers found hES cells to be 
adequate substitutes to older or damaged spinal cord tissue through differentiation.  Hans 
Keirstead and his colleagues discovered a way to use hES cells to restore neuron insulation in 
rats treated one week after a spinal injury was induced.  The UC Irvine team created a way for 
hES cells to differentiate into oligodendricytes which form myelin sheaths that coat the neurons 
and insulate them. The treatment led to a full recovery of the rat’s motor skills.  The 
oligodendricytes wrapped around the damaged neurons and slowly formed the myelin sheath that 
originally protected the area, eventually leading to healthy neuronal activity and increased motor 
skills from the rats.   
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This same procedure was tested on rat’s injured for approximately 10 months, however 
the results were the opposite showing the technique only works if it is administered shortly after 
injury (Stem Cell Treatment, 2005).  The myelin never formed because of the presence of scar 
tissue that had formed (Stem Cell Treatment, 2005). 
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CHAPTER-3:  STEM CELL ETHICS 
 
 
 
 So far we have discussed the various types of stem cells, ranging from pleuripotent ES 
cells, to ES cells derived from parthenote eggs, to ASCs, to stem cells produced by somatic cell 
nuclear transfer, to stem cells derived from adult fibroblasts induced to de-differentiate into iPS 
cells.  We have also discussed the incredible potentials they have to treat various diseases and 
make breakthroughs in the field of molecular science.  Although these cells could be of very high 
value to society, some types come with strong ethical concerns, particularly those that involve 
the destruction of an embryo, or that involve cloning.  The purpose of this chapter is to discuss 
some of the ethical concerns surrounding this controversial topic. 
 The major ethical conflict with stem cells comes primarily from the use of ES cells, 
because many people believe the embryo used to obtain the valuable cells is a precursor to a 
human being.  Thus the discussion of ES cells revolves around the definition of human life, the 
status of the human embryo, and especially when personhood begins and ends.  For most people, 
their own religions teach them important values in life, and it is notable that each religion 
emphasizes its own beliefs of how valuable human life is at different stages, and how far one 
must go to protect it.   Most people have faith and trust in their own religion, and they rely on it 
to help them decide about stem cell research.  The ethical debate on the use of ES cells is 
relatively complex, and even leaders within one religion disagree on the topic.   
 From the outset it should be stated that none of the five major world religions as dis- 
cussed below are against working with adult stem cells.  These ASCs do not destroy an embryo 
to obtain them, and are provided with adult donor consent.  Thus, most of this chapter will focus 
on the ethics of ES cells, parthenotes, SCNT cells, and iES cells. 
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Christianity and Embryonic Stem Cells 
 
 Christianity is one of the most followed major world religions.  Approximately 33% of 
the world population follows Christian beliefs, making it a widespread and well-followed 
religion (Major Religions…2005).  In turn, the Christian religion has a diverse level of complex- 
ity; it is divided up into the major sects [Roman] Catholic and Protestant, with the Protestant sect 
further divided into separate churches such as South Baptist Convention and American Presby- 
terian Church.  Despite the various denominations, most sects follow a form of general Christian 
belief, and believe life is defined as beginning at conception, when the sperm cell fertilizes the 
egg cell.  Thus, most Christians firmly support the preservation of life.   
The Roman Catholic Church has had quite a varied historical past.  In past traditions, by 
order of the disciples Augustine of Hippo and Thomas Aquinas, the church maintained for 
centuries the adopted Aristotelian view that life begins 40 days after conception, the time of 
ensoulment.  Such a view would have allowed 5-6 day old embryos to be used to derive ES cells.  
But after 1869, the Catholic Church discredited this doctrine, and established a newer view 
requiring that human life be protected at the earliest possible time, which is taken to be at 
conception” (National Academy Press, 2001).  This view was based on a supplanting notion that 
“we cannot know with certainty when human life has really become established” (National 
Academy Press, 2001).  As Roman Catholic Christianity is a conservative sect compared to most 
others, most Catholics are against ES cell research, and the Vatican who is charge of leading the 
beliefs of the Catholic Church defines life as beginning at conception, and has issued a strong 
statement condemning ES cell research for any purpose (Chamany, 2004).  In addition, Roman 
Catholics consider contraception and abortion before the 40
th
 day of gestation as a sinful but 
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nonhomicidal act, and due to the belief that early embryos should be given dignity, theologians 
find it an immoral act to buy or sell embryos that are used in research (Chamany, 2004). 
 In contrast, within Protestant Christian sects, there actually exist diverse views on ESC 
research, and a majority does not support the strict Catholic stance that human life must be 
protected at all times.  Some conservative protestant groups reject the use of embryos for 
research as the Roman Catholic Church, but most Protestants accept ESC research (National 
Academy Press, 2001), to a limited extent.  For instance, the Eastern Orthodox Church defines 
life as beginning at conception, yet it supports therapeutic applications using only existing stem 
cell lines without deriving any new additional embryos (National Academy Press, 2001).  Those 
who follow the American Presbyterian Church approve of ES cell research if the goals are to use 
them for medicinal purposes, and so long as a cure cannot be reached in any other manner.  A 
majority of nonconservative Protestants approve of research on embryos within a limited fifteen-
day window from initial fertilization, and that cannot be used for reproductive purposes (General 
Positions…2006).   
 
Judaism and Embryonic Stem Cells  
 Judaism, one of the oldest known religions, is currently practiced among fourteen million 
people worldwide, or a surprisingly 0.22% of the world population (Major Religions…2005).  
Like Christianity and Islam (the latter of which will be discussed later), Judaism is an Abrahamic 
religion following by adhering monotheism, but its own beliefs on moral and ethical statuses on 
life differ with other conservative religions.  Followers of Judaism follow the way of the Torah, 
or the holy manuscript of the Jewish community.  Rabbis Elliot Dorff and Moshe Dovid Tendler 
explained that in Jewish law and tradition, the embryo has no moral status until 40 days after 
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implantation, which would allow 5-6 day old blastocysts to be researched. Yet, once the embryo 
has implanted in its mother’s womb, the child is viewed as a part of its mother’s body and is 
considered to be alive, although its own life is believed to begin only when the child is born. In 
terms of ES cell research and Judaism, eggs and sperm mixed together in a petri dish have no 
legal status, because they will never implant in a woman’s womb and become part of a true 
human being (National Academy Press, 2001).   
 Furthermore, Jews are responsible to make the best out of the life they gain from God, 
and must abide by the task of healing through their duty to save life (National Academy Press, 
2001).   Thus Jews believe they must rely on ways they feel would be righteous with respect to 
their moral beliefs, to fight disease and create cures.  Although some laws within Judaism pre- 
vent researchers from going overboard experimenting with too many embryos, Jewish sects do 
support ES cell research to a more liberal extent than Christianity.  It can be inferred that Jews 
mandate the use of only excess IVF embryos in stem cell research (Chamany, 2004). 
 
 
 
Islam and Embryonic Stem Cells 
 
 Islam is the world’s second most followed major religion, with about 1.5 billion people, 
or 21% of the world population, following Islamic culture and beliefs.  Sunni and Shi’ite Mus- 
lims constitute the two major sects, with a third minor sect constituting small groups such as the 
Sufis, Druze, and Ahmadiyya (Major Religions…2005).  Muslim faith is based on the teachings 
of the holy Islamic book the Koran and the ways of the Prophet Mohammad, interpreted by way 
of the Shari’ah (Chamany, 2004).  According to Muslim tradition, and emphasized by legal 
literature, a human embryo has no legal or moral status until it has developed into a fetus at the 
end of the fourth month of pregnancy, or about 120 days.  Muslim religious leaders believe that 
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this is the time when ensoulment, or the time when the embryo has become a person, has 
officially taken place.  Thus, it can be inferred that Muslims support ES cell research, as long as 
the embryo is made and sustained in an environment different from the mother’s womb, like the 
laboratory, in which case the embryo does not gain the status of a human being. 
 Similar to Judaism, the holy book of Islam does teach its disciples to control themselves 
and embrace values important in life.  For instance, Islamic law strongly emphasizes spousal 
love and linage, as well as spiritual connections.  It also emphasizes the importance of establi- 
shing a child’s true lineage and inheritance rights, with no immoral action taken to disrupt gene 
flow.  Thus by way of Muslim religious law, ES cell research is carefully regulated and limited 
for the convenience and consideration of especially donors.  And therapeutic cloning is tolerated 
more, compared to reproductive cloning. 
 
 
 
 Buddhism, Hinduism, and Embryonic Stem Cells 
 
 About 376 million people, or about 6% of the world’s population, follow Buddhism, 
another of the world’s major religions (Major Religions…2005).  Compared to the monotheistic 
religions (Christianity, Judaism, and Islam), Buddhism is a polytheistic religion, where there is a 
belief in many gods.  The philosophy Buddhists follow is based on the teachings of Siddartha 
Gautama, the founder of this religion.  Those who follow Buddhism emphasize the power of 
healing, as well as the central virtues of knowledge and compassion, so they welcome the great 
development of curing agents which help alleviate human suffering (Keown, 2001).  However, 
Buddhists believe in the philosophical concept of ahimsa, or nonviolence, which in turn leads 
them to the belief in the prohibition of death and injury to living organisms.  In addition, they 
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believe, like Hinduism, that individual life begins at conception and is entitled to the same moral 
respect as an adult human being (Keown, 2001).  
 As a result, most Buddhists are against using ES cells created from surplus unwanted or 
IVF embryos, or even from SCNT human embryos created for research purposes, as this 
involves the intentional destruction of human life, which they find as an immoral act.  As for 
adult stem cells, Buddhists encourage their use, since through the process of obtaining them, no 
human being is significantly harmed.  Followers of Buddhism encourage the gathering and 
research of stem cells obtained from aborted fetuses, provided the fetuses were already deceased 
by some developmental failure or they had to be removed if the mother was in some sort of dan- 
ger at the same.  This they would consider moral, but they would consider it immoral to harvest 
stem cells from a fetus or embryo, if it was aborted intentionally.  For now there really exists a 
teetering diversity of Buddhist opinion on how ES cells should be regarded, as Buddhists do not 
rely on a central authority to pronounce on these ethical dilemmas (Keown, 2001), and it is 
obvious that Buddhists find it hard to really deal with ES technology. 
 Hinduism is another major religion, practiced by about 14% of the world population.  
Much like in Buddhist philosophy, traditional Hindu beliefs believe that conception is the 
beginning of a soul's rebirth from a previous life (when personhood may begin). Hindus, like 
Buddhists, find abortion a denouncing procedure, as they believe that the fetus has a right to live.  
They also believe by way of Hindu doctrine that it is not immoral to perform stem cell research 
on embryos created in an IVF clinic, so long as the embryos are not implanted. 
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Non-Religious Viewpoints of Stem Cell Ethics 
 It is evident from our discussion so far, that in view of religion, human life is greatly 
valued and different moral guidelines based on thoughtful belief are in effect for each religion.  
Although religion certainly has a major say in individual beliefs, some people have their own 
views on what they feel would be just and appropriate to society.  For instance, some individuals 
would find (based on their own non-religious beliefs) that it is permissible to derive new ES cell 
lines from “excess” IVF embryos produced for reproductive purposes, so long as they are really 
no longer needed for reproductive purposes, and so long as the donors consent.  In the case of 
embryo discard, some individuals might even consider it immoral to discard them without trying 
to save human lives by extracting ES cells.  With current ES cell technology, obtaining good 
quality ES cell lines is a tough process, so having a larger numbers of IVF embryo donors  would 
help improve the overall quality of ES cells for therapy.   
The debate behind using excess 5-6 day old IVF embryos for research, that have no 
developed nervous system, no brain, no eyes, no limbs, no heart, etc., pales in view of the debate 
to use much older fetal tissue donations where some claim “unborn human beings are harvested 
for cells they might provide to another human being” (Wright, 1999).  Here the debate focuses 
on using aborted fetuses to provide tissue, and which types of abortion are allowed (elective 
abortions,  spontaneous abortions, or abortions to save the life of the mother)? 
 
Parthenote and Somatic Cell Nuclear Transfer Ethics 
 As discussed in Chapter-1, parthenogenesis is a possible alternative to obtaining ES cells 
from a fertilized embryo.  This process involves the self-fertilization and stimulation of a haploid 
ovum in vitro to reach a blastocyst stage where pleuripotent-like stem cells can be obtained, but 
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the embryo is not capable of any further division.  Although parthenotes cannot become human 
beings, to most religions parthenogenesis comes with impractical problems.  Based on recent 
experiments conducted on parthenotes, only a few ES cell lines have been established through 
the use of large quantities of eggs.  As a result, parthenotes do not yet provide a reasonably 
efficient means to obtain ES cells.  In addition, since the eggs required for this procedure come 
from women, moral dilemmas arise concerning collecting eggs from women’s ovaries for 
therapeutic purposes (Kiessling, 2005). 
 Somatic Cell Nuclear Transfer, or SCNT, has been described as a technique used to 
create a line of ES cell-like cells that are genetically identical to the original donor.  It involves 
the transfer of a donor’s somatic cell’s genetic material into an enucleated egg, which is then 
stimulated to divide to the blastocyst stage from which ES-celllike cells are obtained.  So far it 
has been shown that this procedure works in mice, but not yet in humans.  The ES cells carry the 
same genome as those of the original donor; thus a patient could in theory be treated with his 
own ES cells.  SCNT is a type of therapeutic cloning.  Despite the valuable practicality that may 
come with SCNT, SCNT has strong ethical opposition.  Some people find the termi- nation of 
the blastocyst after removal of the ICM cell mass a morally and ethically objectionable matter.  
SCNT could be also be applied to reproductive cloning, where the blastocyst formed from SCNT 
would be implanted in the womb to develop to full term to become a clone instead of being 
destroyed.  Thus, most religious groups and governments find this process worthy to take a stand 
against, and especially find it immoral and unnatural for a person to be created without two 
parents.  Because of these major probable concerns, most governments have laws in effect 
banning [human] SCNT technology, which shall be further discussed in Chapter-4. 
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Ethics Behind iPS Cells 
 
 As discussed in Chapter-1, induced pleuripotent (iPS) stem cells represent another 
possible alternative to obtaining ES-like cells without having to destroy an embryo.  The process 
involves obtaining a number of convenient adult somatic cells, such as skin cells, and 
reprogramming them so that they are induced to an ES cell-like state.  This reprogramming is 
done by means of inserting copies of combinations of three or four genes encoding transcription 
factor proteins into the cells’ nuclei, with the aid of pragmatic retroviruses.  It can be noted that 
no embryo is formed or destroyed through this procedure, and no [donor] eggs are required to 
obtain pleuripotent cells, thus the production of iPS cells does not raise as many critical concerns 
as ES cells, parthenotes, or SCNT.  The production of iPS cells is actually an inefficient 
procedure, only 5% of the treated cells are fully reprogrammed (Cyranoski, 2008), but the re-
programmed cells can be amplified.   
Although iPS cells in theory can be created genetically identical to a patient to avoid 
immunorejection, for now it is impractical to produce large numbers of patient-specific stem cell 
lines for everyone, so for now iPS therapies would focus on providing iPS cells with as close an 
immunological match as possible.  The genetic engineering technique (transfection) used to 
make iPS cells is considered relatively easy according to Dr. Shinya Yamanaka, “…many people 
can do this – and without telling anybody” (Cyranoski, 2008).  But it is expensive, so the rich 
could pay to have an iPS line generated specific to them (Cyranoski, 2008), raising a different 
type of ethical concern.  In addition, some might use iPS cells to derive gametes, which may be 
used in an in vitro fertilization procedure; this to most people would be considered strange and 
potentially dangerous, allowing human reproductive cloning, a currently illegal procedure.   
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Chapter 4:  Stem Cell Legalities  
  
  
 Stem cell research is a very young experimental field where many questions arise 
pertaining to the ethics of where these cells originate from.  As is typical for most controversial 
technologies, regulations have been laid down by federal and state legislatures to govern this 
emerging field.  However, questions arise as to whether these regulations hinder stem cell 
research from achieving its true potential as a life saving treatment for injuries and diseases. 
 
U.S. Federal Funding for ES Cells 
            Federally funded research involving the use of human embryonic stem cells (hES’s) has 
been hindered in the U.S. because of philosophical and political views surrounding where these 
cells are obtained.  As mentioned in earlier chapters, ES cells are obtained from the inner cell 
mass of a 5-6 day old blastocyst created by in vitro fertilization.  Harvesting the ES cells destroys 
the blastocyst which if implanted into a uterus had the potential to become a human being, thus 
creating the ethical quagmire.  U.S. scientists are finding it hard to continue such research due to 
so many uncertainties and laws surrounding the field.  Many of the scientists that propose ES 
research on different diseases or injury are either shut down due to lack of funds, or their 
research is declared illegal and unethical.  Keith Yamamoto who is Vice Dean for Research at 
the University of California School of Medicine states that “ It’s too much work to put together a 
research proposal only to find out it’s going to be made illegal, or that there will be a four year 
moratorium proposed”  (Agnew, 2003). 
In 1993, while Bill Clinton was in office, an act called the National Institutes of Health 
Revitalization Act was constructed by Clinton and Congress approving the funding for human 
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embryo research.  NIH gathered a group of advisors, including scientists, ethicists, public policy 
experts, and patient advocates, whose purpose was to make recommendations.  One of the NIH’s 
recommendations was to allow spare human embryos to be used to obtain ES cells.   In 1995, 
congress found that federal funding for the creation and/or destruction of human embryos was 
unethical and so it was banned in the Dickey-Wicker Amendment.   This amendment was named 
after the congressmen who developed the amendment, Jay Dickey a republican from Arkansas, 
and Roger Wicker a republican from Mississippi (Dunn, 2005). 
 In early January of 1999, Harriet Rabb concluded that since human embryonic stem cells 
are not actually a human embryo, the Dickey-Wicker amendment does not include these types, 
so it is possible to utilize ES cells.  The then new Clinton administration guidelines implemented 
during August of 2000 allowed research with ES cells that privately funded scientists had already 
taken from spare embryos that were set up for destruction at fertility clinics.  The Clinton 
administration truly opened the door for federal funding of such research, until it was shut down 
by President Bush in 2001 (Dunn, 2005). 
 In 2001, a law was passed by President George Bush stating that scientists receiving 
federal funding for research may only use ES cells that existed before August 9, 2001 (Agnew, 
2003).  Although initially there appeared to be approximately 60 ES cell lines meeting this pre-
2001 criterion, further testing revealed in actuality there is only about 9 unique ES cell lines left.  
This is apparently also scaring scientists away from performing research since not enough of 
these stem cells are available. 
            President Bush also feels strongly against the idea of human cloning, and he urges 
congress to ban such ideas and research.  Legislation to ban the use of somatic cell nuclear 
transfer (SCNT) (the technique utilized to clone Dolly the sheep) was introduced to the U.S. 
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senate and the House of Representatives.  Nearly one hundred co-sponsors were attracted to this 
house bill within only a few days of its circulation (Agnew, 2003).  However, another bill was 
also introduced to the senate for debate that would allow SCNT for therapeutic purposes only, 
and would ban human reproductive cloning (Agnew, 2003).  In this therapeutic process, the 
nucleus from a patient’s fibroblast skin cell would be introduced into an enucleated egg, then the 
egg is grown in vitro to the blastocyst stage from which ES cells can be derived that are 
genetically identical to the patient.  Therapeutic cloning would allow ES cells to be created that 
are specific for a patient (not immuno-rejected).  Essentially, the person whom needs treatment 
would allow the researcher to utilize his or her own somatic cells from which ES cells could be 
grown.  Transplanting such cells would lead to no immunological problems since the cells were 
their own from the beginning.  SCNT has been successfully achieved with some animal species, 
but not yet with humans.  It is important to note that both types of SCNT (therapeutic and 
reproductive) involve embryo destruction.   
Proponents for both sides of the argument have currently created a stalemate in the 
Senate where neither side can officially overrule the other.  However, even if a stem cell bill 
passed the Senate, the House would more than likely disagree.  And even if the bill made it 
through Congress, President Bush would likely veto the bill (Agnew, 2003).  The House of 
Representatives has twice prohibited all forms of cloning in 2001 and again in 2003 (Dunn, 
2005).   U.S. Senator Hatch argued for the use of SCNT saying, “Even those who believe that 
life begins at conception, even if the union of sperm and egg takes place in the lab, need to 
consider carefully whether the joinder of an enucleated egg with a somatic cell nucleus, 
accompanied by chemical or electrical stimulation, should fairly be thought of as the same 
process as conception” (Agnew, 2003). 
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During June 2004, 58 US senators delivered a letter to President Bush urging him to 
allow more of the available ES cell lines to be federally funded for research.  This group 
included 14 republicans as well as two well known abortion opponents.  In March 2005, the 
House of Representatives drafted a bill which would allow federal funding of research on ES 
cells, however Bush vetoed the legislation (Dunn, 2005). 
 
 
Individual States and Stem Cells 
            Numerous states, including New Jersey, Massachusetts, and California have passed laws 
allowing state funds to be used to support ES cell research.  Some of the larger educational 
institutions have created stem cell institutes that use money received from state bonds.  These 
institutions include Stanford, UCSF, and the University of Massachusetts Medical Center 
(Worcester) (Agnew, 2003). 
 One of the most prominent stem cell states in the US is California, where the people have 
approved a $3 billion dollar bond funding stem cell research to be utilized over a 10 year period.  
The California legislation also passed proposition 71 where California became the first state to 
appropriate money for this type of research.  Approximately 11% of the US’s biotech scientists 
are currently employed in research facilities in California (Stem Cell Legislation, 2005).  The 
California law allows the use of human ES cells and SCNT embryos for research, but the cloned 
embryos cannot be used reproductively.  California was the first state in the US to pass such a 
law.  
In 2004, New Jersey established a state funded stem cell research facility (Stem Cell 
Legislation, 2005).  Later on that year, proposition 71 was passed which allowed $3 billion 
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dollars to be dispersed over a 10 year period to the stem cell research facilities in California 
(Stem Cell Legislation, 2005).   
In Massachusetts, legislation was introduced in 2005 to allow state funds to support ES 
research, but then governor Mitt Romney vetoed the bill twice (Dunn, 2005).  Under Governor 
Patrick, the Massachusetts legislation approved a Bio-initiatives bill for about one billion dollars 
to fund stem cell research, which passed both the state senate and house in 2007, and the funds 
were released in 2008 (Dunn, 2005).  
In Maine, the law prohibits the use of in vitro fertilized embryos post implantation for 
research.  In New Hampshire, it is prohibited to use unfrozen fertilized embryos after 14 days 
(although this allows the use of 5-6 day old blastocysts for obtaining ES cells).  On the other 
hand, in New York stem cell research is greatly encouraged.  In January of 2006, the state 
decided to fund the New York State Institute for Stem Cell Research and Regenerative Medicine.  
A total of about $300 million will be dispersed to the research center, some of it going towards 
ES cell research (Stem Cell Legislation, 2005). 
 
International Stem Cell Legislation 
The stem cell legislation in different countries (see Figure-1) can be loosely divided into 
conservative (yellow), moderate (light brown), or flexible (dark brown).  Examples of 
conservative countries include the U.S., Argentina, Africa, Italy, and Germany.  Moderate 
countries include Canada, Brazil, and Spain.  Countries with flexible stem cell policies include 
England, Sweden, Finland, India, China, and Australia. 
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Figure 1:  World Diagram Showing Stem Cell Legislations.  This diagram shows various countries labeled for 
their stem cell laws as being conservative (yellow), moderate (light brown), or flexible (dark brown) (Hoffman, 
2005). 
 
 
In South Korea, a corporation known as the World Stem Cell Foundation, led by the 
south Korean researcher who claimed to be the first to clone a human embryo for the creation of 
stem cells (and who later admitted to fraud) has begun producing approximately 100 new cell 
lines annually and to make them available to scientists, mainly those in the US that are struggling 
because of limited federal funding.  This is a way to go around the policies laid down by 
President Bush and to acquire these new stem cell lines from overseas (Kaplan, 2005). 
 In February of 2002, the German parliament voted to allowing the import of human ES 
cells into the country.  This would be allowed only under close government supervision.  The 
current German law bans all research on human embryos, allowing IVF only for reproductive 
purposes.  The German parliament also passed a law that stated that researchers can only use 
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stem cells that have already been created and new cell lines cannot be created within this country 
(Kim, 2002). 
 The French are also fighting through ethical issues on whether to allow the use of 
imported stem cells.  A 1994 French law states that research on human embryos is prohibited.  
Sweden on the other hand, one of the world leaders in stem cell research, recently received 
support by two governmental ministers urging the cloning of human embryos for therapeutic 
purposes.  Dr. Jochen Taupitz who is a member of Germany’s National Ethics Council states, “In 
a European comparison, Germany has some of the strictest laws, so even with this resolution we 
are pretty isolated in Europe.  In all countries there’s a fierce debate.  There’s no country in 
Europe where there is a unanimous opinion on this issue” (Kim, 2002). 
 Germany is such a large European player when it comes to stem cell research that as long 
as the regulations for such experimentation hold strong, the rest of the surrounding countries will 
more than likely continue to follow suit.  Only time will tell what affect this power will have on 
other smaller countries might have, such as Austria, Portugal, and Ireland (Davies, 2003). 
   Sweden, as stated earlier, is one of the leading countries currently performing research 
on ES cells.  Sweden’s stem cell community is backed by strong moral support from it’s 
occupants, as well as reliable government funding and a great bioethical environment.  There are 
approximately 30 plus research groups found in Sweden,  and approximately 300 scientists 
working at numerous institutions around the country.  Sweden is the only country that allows 
stem cells to be extracted from embryos that are no longer being utilized.  With such freedoms, 
Sweden is one of the most successful biomedical science and research locations in the world.  In 
March of 2002, Sweden joined with the US to create additional funding in the ballpark of about 
$7.5 million dollars to benefit stem cell research on Swedish grounds.  The Secretary General of 
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the Medicine section at the Swedish Research Council states, “The entire stem cell field is on the 
threshold of development.  These grants are extremely important for advancing research so that 
we can identify areas with the greatest potential.  Today, we hope that stem cells will eventually 
be able to cure a number of diseases, but before we can say if and when this will be possible, 
much intensive research is needed”  (Sweden Stem Cell Success, 2002). 
 
Chapter Conclusion 
  As one can see, a great deal of ethical/moral decisions must be made by many people on 
the topic of stem cell research, and these decisions affect state and federal laws.  The key to this 
situation is that people must begin to understand the benefits of such research and the medical 
advances that await, as well as the ongoing research to create alternative sources for ES cells.  
We have the key to the future of regenerative medicine, but we must cautiously use this gift and 
not abuse it.  People must understand that in some situations, using adult stem cells does not 
involve the killing of a baby fetus or the destruction of a life.  And even for ES cells, the extra 
IVF embryos are already slated for destruction, so perhaps they could be used instead to try to 
save lives.  In the end, this research is pro life, and can only benefit our chances at long, disease 
free, healthy lives.  Before one makes a judgment on the subject I urge them to think carefully 
and to understand what stem cell research can do to modern medicine and the positive changes it 
can have on many people’s lives that are suffering and need these medical breakthroughs.  
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CONCLUSIONS 
 
 
 
 The purpose of this IQP was to investigate stem cell technology, examining a variety of 
stem cell types, as well as the ethics and legalities surrounding their research.   We conclude that 
different from what is commonly thought, not all stem cells are alike, and not all of them require 
the destruction of an embryo.  Embryonic stem (ES) cells have the greatest medical potentials, 
but the greatest ethical and legal concerns.  Adult stem cells (ASCs) are more difficult to grow, 
and have less differentiation potential, usually restricted to forming the main tissue from which 
they were obtained.  We support the development of new alternative technologies, such as iPS 
cells, that avoid the destruction of embryos to obtain ES cells.  We conclude that of the five 
major world religions, Christianity (especially Catholics) and Buddhism oppose ES cell research, 
while the 3 others are somewhat supportive of it.  All five support adult stem cell research.  
Legal restrictions placed on stem cell research by countries such as the U.S. and Germany have 
hindered research into ES cells relative to other more progressive countries.  
 
